Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging study.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Microglial dysfunction and glutamatergic dysregulation are implicated in the neurobiology of schizophrenia. Microglia regulate brain glutamate levels through mechanisms including the cysteine-glutamate antiporter, raising the possibility that microglial dysfunction could underlie glutamatergic dysregulation in schizophrenia. We tested this using a combined cross-sectional/longitudinal study of individuals with first episode psychosis and healthy controls. We investigated two hypotheses: (1) increase in a positron emission tomography (PET) imaging marker of microglia is associated with increased anterior cingulate (ACC) glutamate levels; and (2) reducing immune trafficking into the CNS using the monoclonal antibody natalizumab would reduce ACC glutamate levels in people with first-episode psychosis. A total of 108 participants (68 patients and 40 healthy controls) underwent simultaneous proton magnetic resonance spectroscopy to quantify ACC glutamate and glutamate/glutamine (glx) levels and PET imaging with [18 F]DPA-714 to quantify translocator protein (TSPO) levels, a protein highly expressed by microglia in neuroinflammatory conditions. In the longitudinal arm, 50 first-episode psychosis patients were included and either randomised to receive natalizumab or placebo double-blind, or received open-label natalizumab. At baseline, there was no significant association between ACC glutamate concentration and ACC TSPO binding in the entire sample (β = -0.003, SE = 0.006, p = 0.55). In the longitudinal arm, natalizumab did not significantly alter ACC glutamate levels (mean difference = 0.227 i.u., t = 1.52, p = 0.139). These findings do not support the hypothesis that microglial dysfunction drives ACC glutamatergic dysregulation in early psychosis. Microglial dysfunction and glutamatergic dysregulation may therefore represent distinct mechanisms within the neurobiology of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.